Criteria Bio Ventures
@CriteriaBioVC
Followers
35
Following
16
Media
7
Statuses
18
Criteria Bio Ventures is a leading life sciences venture fund looking to partner with transformative companies to shape the future of healthcare.
Joined January 2024
Pleased to have participated in the oversubscribed $17.2M seed financing of Tolerance Bio, a Philadelphia based #biopharma pioneering thymus-based therapies for immune-mediated diseases. News here: https://t.co/aNHjz2kt8N
#portfolionews #venturecapital #biotech #immunology
1
0
1
@sanofi @Amgen Proud to welcome Tolerance Bio to our portfolio and support its innovative programs in the exciting field of thymus-based therapies! Learn more about Tolerance Bio & this financing: https://t.co/aNHjz2kt8N
#portfolionews #venturecapital #lifesciences #financing #autoimmunity
tolerancebio.com
Philadelphia, PA – Oct. 15, 2024 – Tolerance Bio, Inc., a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the...
0
0
1
@sanofi @Amgen Tolerance Bio is developing an allogeneic, or “off the shelf”, thymus iPSC-based #celltherapy platform along w pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance like autoimmune diseases, transplant rejection & cancer
1
0
1
Industry veteran Francisco Leon, co-founder & CEO of Tolerance Bio, will lead an experienced executive team to develop novel approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance
1
0
0
Proud sponsors one more edition of @CataloniaBioHT #BBQ2024. See you all next week at one of the best #biotech summer events in town!
🟢 Hurry up! The #BBQ2024 is back next week and there are very few tickets available! 😎 👉 https://t.co/GjS0r2ZAZ3 🙌 Our sponsors: 🥇/deeplabs, @leanbiopro, @GPPharm, @YsiosCapital 🥈@AsabysPartners, @Asphalion, @CriteriaBioVC , @inveready, @InvivoCapital @merckgroup
0
1
0
📢Pablo Cironi (@CriteriaBioVC) resume los highlights de su intervención y el papel de Caixa Capital Risk 📍Taller 'Introducción a la Innovación y Transferencia en Biomedicina y Salud' de ASEICA-@FundlaCaixa @msmelanoma ℹ️: https://t.co/ZGRiLRYpAn
0
1
3
We are attending @AseBio Investor Day! A fantastic event to feel the pulse of the Spanish biotech ecosystem. #AseBioID2024
0
0
0
Next week we will be attending #BioEquityEurope 2024 in San Sebastian to meet #biotech entrepreneurs and catch up with #pharma industry leaders and fellow #venturecapital investors. If you are also participating, get in touch with us to arrange a meet up! 🤝
0
0
0
Today we attended the second edition of @CataloniaBioHT #ConnectionDay24
🔛🟢 The second edition of the #ConnectionDay24 is on! Many thanks to all attendees for your trust and for having exceeded expectations, once again, this year. Let networking and connections begin! #WeAreCataloniaBioHT
0
0
1
Next week we will be attending #BIOEuropeSpring 2024 in Barcelona to meet #biotech entrepreneurs and catch up with #pharma industry leaders and fellow #venturecapital investors. If you are also participating, get in touch with us to arrange a meet up! 🤝
0
0
0
Thrilled to announce the well-deserved promotions of @RubenSebas_ and Salvatore Cappadona to Senior Associates within our investment team 🚀 Their exceptional talent and invaluable contributions have been instrumental in driving our mission forward. Congrats Ruben & Salvatore!
0
0
1
Today Pablo Cironi, Managing Director, and @RubenSebas_, Sr Associate, are representing @CriteriaBioVC at CNIO Investor's Day 2024. A great event to interact with the scientists of one of the leading cancer research centers worldwide. @CNIOStopCancer
#cancertherapy #innovation
0
1
1
Our portfolio company @Inbiomotion and @SourceBio have signed an exclusive agreement for MAF Test® in the UK and Ireland. The MAF Test® will benefit ~56,000 new #breastcancer patients each year. More info 👉 https://t.co/PGwMRhaa2x
#CBVnews #portfolionews #oncology
0
2
2
#tbt last year we welcomed AbolerIS Pharma! We led the €27.3M Series A round of AbolerIS, a Belgian #biotech developing a novel immunotherapy for autoimmune and inflammatory diseases. #CBVnews #portfolionews #immunology #autoimmunity #venturecapital
https://t.co/AHOGrkWOOy
aboleris-pharma.com
0
0
0
Meet the @CriteriaBioVC team! Stay informed about the latest news from our portfolio. Follow us on this new account for updates on our #biotech and #lifesciences investments and team activities! @CriteriaBioVC web➡️ https://t.co/QpPaqykoGT
#biotech #lifesciences #pharma
0
2
5
We are launching new @X profiles! From today we will share our #VC activity on #Tech topics from the account @CriteriaVT. Everything related to #Biotech and #LifeSciences will be available at @CriteriaBioVC. Follow us ⬇️! 🔬 https://t.co/QpPaqykoGT 🤖 https://t.co/WbmbjgN72i
0
1
4
Exciting news! Our new website is live, providing a fresh look into Criteria Bio Ventures. Follow us for updates on our portfolio, team activities, and more. Let the journey begin! 🚀 #CBVnews #venturecapital #biotech #lifesciences #pharma
https://t.co/MV7pBNuP7p
criteriabioventures.com
Supporting life-changing therapies through long-term strategic partnerships
0
2
4